secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2023-06-07T23:59:59+00:00
Accession:  0001104659-23-068637
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx gets Nasdaq extension to July 30, 2023 for continued listing; ELX-02 pivotal study planned
--------------------------------------------------------------------------------

- Nasdaq Hearings Panel granted extension through July 30, 2023 to regain compliance with $35M market value rule.
- Extension is conditioned on achievement of certain milestones included in a compliance plan.
- Company plans to advance ELX-02 into pivotal study in Alport Syndrome patients with nonsense mutations.
- Plans depend on completing third patient dosing in Phase 2 trial, FDA discussions, and obtaining necessary capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923068637/0001104659-23-068637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923068637/tm2317998d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-068637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer